PETALING JAYA: CIMB Securities Research has upgraded Genetec Technology Bhd
to a “buy” call from “reduce” after the group returned to the black in its first quarter ended Sept 30, 2026 (1Q27).
Genetec recorded a net profit of RM490,000 in 1Q27, compared with a net loss of RM42.3mil in the corresponding quarter a year earlier, while revenue inched up to RM34.87mil from RM34.34mil.
CIMB Research said the results were in line with expectations, with a core net profit of RM566,000 after five loss-making quarters, supported by “cost discipline and revenue momentum.”
It said the earnings recovery could partly reflect improving order replenishment from North American and e-mobility customers, alongside early progress in customer diversification efforts.
Looking ahead, the research house said it is “increasingly positive” about Genetec’s earnings recovery prospects in the financial year ending June 30, 2027 (FY27), as improving order conversion is expected to strengthen operating leverage.
“We estimate Genetec secured over RM150mil in new orders year-to-date, driven by healthy order replenishment from North American and e-mobility customers, alongside new customer wins,” it said.
“We believe the progressive conversion of these orders over the next nine to 12 months should support stronger revenue growth and better fixed-cost absorption, underpinning further margin recovery.”
The research house said that Genetec was pursuing growth opportunities in adjacent automation and energy-related segments, which, if successfully converted, could diversify its revenue streams, reduce customer concentration risks and strengthen earnings resilience over the medium to long term.
It also noted improvements in the group’s balance sheet, with trade receivables declining 35.9% to RM108.6mil as at end-September 2026 from RM169.3mil at end-June 2026, “suggesting improved collections”.
Net gearing also fell to 8.7% from 21.1% over the same period.
“Overall, we view the return to profitability and improved financial position as early signs of progress in the group’s cost optimisation and margin preservation strategy,” it said.
Following the upgrade, the research house raised its target price to 33 sen from 21 sen previously, while keeping its earnings forecasts unchanged.
It also raised its target price-to-book value multiple to 0.75 times, in line with Genetec’s five-year mean.
